Angiotensin II receptor blockers (ARBs) helps in blocking angiotensin II action, allowing the blood vessels to dilate. Angiotensin II are chemicals in the human body that affect the heart by narrowing down the blood vessels, not allowing the required space to the blood to move, resulting in increasing blood pressure, known as hypertension, and cardiovascular risks. Leading brands in the ARB market include Benicar (olmesartan medoxomil), Diovan (valsartan), Micardis (telmisartan), Cozaar (Osartan), Edarbi (Azilsartan), Atacand (candesartan), Teveten (eprosartan), and Avapro (irbesartan). ARBs help in the treatment of conditions, such as, high blood pressure, heart failure, chronic kidney diseases, and kidney failure in diabetes. Hypertension and cardiovascular risks are interrelated. Increase in blood pressure can cause high cardiovascular risk in patients. According to the World health Organization, blood pressure is the most prevalent cause of heart failure, resulting in increasing mortality rates. ARBs are available in generic and under specialty brands also. ARBs are a popular choice for treating high blood pressure and are usually recommended to the patients under 55 years of age. Clinical studies have proved that the side effects of ARBs are negligible; besides, ARBs are comparatively inexpensive. Increase in the availability of generic ARBs has created various options for the patient population. 

ARB drugs are found to have least number of side effects in patients / users, which in turn increases its demand and hence is more preferred than other hypertension drugs. ARBs are gaining popularity as they have the capability of improving the quality of life of the patients. Unlike ACEIs (Angiotensin converting enzyme inhibitors), ARMs do not cause cough or danger of swelling of the lips, throat, or tongue. Moreover, growth in patient population is augmenting the market for ARBs drugs. These drugs are generally preferred over other drugs, as certain studies have suggested that AMBs are also effective in preventing stroke and dementia. Loss of exclusivity leading to increased generic competition, is major restraint for growth of angiotensin II receptor blockers (ARBs) market. Furthermore, compared to ARBs, ACIEs have special advantage for patients with diabetic nephropathy and those suffering from chronic kidney diseases, resulting in dysfunction of kidneys. Moreover, patent expiry of antihypertensive drugs, such as, Benicar and Diovan hinders the growth of the angiotensin II receptor blockers (ARBs) market. In 2018, FDA recalled the list of valsartan drugs as it is linked to cancer, and is anticipated to affect the angiotensin II receptor blockers (ARBs) market. Increasing cases of hypertension, heart failure, obesity, unhealthy lifestyle choices are boosting the demand for ARBs. However, growing commercial availability of ARBs as a generic medicine is leading to adverse effects in patients, resulting in hospitalization or consultation. 

The global angiotensin II receptor blockers (ARBs) market can be segmented on the basis of region, application, and distribution channel. Based on the application, ARBs are used majorly in the treatment of hypertension, cardiovascular risks, and others. In terms of distribution channel, the market caters to hospital pharmacies, online pharmacies, and retail pharmacies. Based on region, the global angiotensin II receptor blockers (ARBs) market has been studied across North America, Europe, Asia Pacific, the Middle East, and Latin America. North America dominates the global angiotensin II receptor blockers (ARBs) market due to availability of accurate treatment options, advanced health care infrastructure, and early diagnosis process. Increasing obesity rate in North America is also one of the reasons for the dominance of the region on the global market, followed by Europe and Asia Pacific. 

Leading players operating in the global angiotensin II receptor blockers (ARBs) market include Daichii Sankyo, Lupin, Novartis, Abbvie, Takeda, AstraZeneca, and Zydus Cadila.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:

  • Market segments and sub-segments
  • Market trends and dynamics
  • Supply and demand
  • Market size
  • Current trends/opportunities/challenges
  • Competitive landscape
  • Technological breakthroughs
  • Value chain and stakeholder analysis

The regional analysis covers:

  • North America (U.S. and Canada)
  • Latin America (Mexico, Brazil, Peru, Chile, and others)
  • Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
  • Eastern Europe (Poland and Russia)
  • Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
  • Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

  • A complete backdrop analysis, which includes an assessment of the parent market
  • Important changes in market dynamics
  • Market segmentation up to the second or third level
  • Historical, current, and projected size of the market from the standpoint of both value and volume
  • Reporting and evaluation of recent industry developments
  • Market shares and strategies of key players
  • Emerging niche segments and regional markets
  • An objective assessment of the trajectory of the market
  • Recommendations to companies for strengthening their foothold in the market   

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.       

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

REQUEST CUSTOMIZATION

Angiotensin Ii Receptor Blockers Market

Pre Book